

Evaluation of Medication Tapering on the Sensitivity of the Spinal Cord Using Closed-Loop Spinal Cord Stimulation (Pilot Study)

NCT07502612

Status RECRUITING
Sponsor Brai²n
Enrollment 20 participants

Key Eligibility Criteria

Inclusion (11)

- Candidate for SCS and scheduled for trial with Evoke system.
- Diagnosis of FBSS or FNSS (PSPS-T2).
- Current use of e1 qualifying pain medication at or above minimum daily dose:
- Gabapentin e150 mg
- Pregabalin e75 mg
- ... and 6 more (see full listing online)

Exclusion (6)

- Active disruptive psychiatric disorder or condition impacting pain perception or compliance.
- Progressive neurological disease (MS, CIDP, progressive arachnoiditis, progressive diabetic neuropathy, brain/spinal tumor, severe spinal stenosis).
- Coagulation disorder, platelet dysfunction, progressive vascular disease, or uncontrolled diabetes with procedural risk.
- Active systemic or local infection.
- Pregnancy.
- ... and 1 more (see full listing online)

Locations (1 total)

Brai²n - ZAS Augustinus, Wilrijk, Belgium